Pharmaceutical Technology

AUGUST 11, 2022

Using data from the UK Biobank database, genomic sequencing data for 360,000 individuals were obtained and the findings were confirmed in animal models that demonstrated a higher expression of the INHBE gene in obese monkeys when compared to more lean monkeys.

Gene 130

Gene Biobanking Gene Expression In-Vitro 130

Drug Discovery World

MARCH 26, 2024

More importantly, it also highlighted that significant challenges remain in selecting the right therapies for the right patients despite the progress made through genomic testing and implementation of circulating tumour (ct) DNA analyses. We were there to present the latest findings from our research.

RNA 64

RNA In-Vivo In-Vitro DNA 64

Drug Discovery World

MARCH 23, 2023

Consistent with first-generation PI3Kdinhibitors, roginolisib inhibits the in vitro growth of lymphoma cells. iOnctura, a clinical stage biotechnology company developing cancer therapies, has published non-clinical research on roginolisib in the AACR journal Cancer Research Communications.

Research 98

Research In-Vitro Clinical Research Genome 98

BioSpace

JULY 3, 2022

Rather than selling, Novartis could spin Sandoz off into its own separate entity with its own listing on a stock exchange.

Marketing 40

Marketing In-Vitro Genome Genomics 40

The Pharma Data

MARCH 31, 2023

Better understanding of enzymes and their functions would be a boon for research in genomics, chemistry, industrial materials, medicine, pharmaceuticals and more. Woese Institute for Genomic Biology at Illinois. ” The researchers verified their tool experimentally with both computational and in vitro experiments.

Protein 40

Protein Genome Genomics Engineer 40

The Pharma Data

DECEMBER 22, 2020

Available since 2017 as an in vitro diagnostic assay (IVD) in Europe and the United States, Japanese clinical geneticists can now have access to this assay to help identify a definitive genetic diagnosis for their patients. SANTA CLARA, Calif.–( –( BUSINESS WIRE )– Agilent Technologies Inc.

Genome 40

Genome Genomics Genetics In-Vitro 40

pharmaphorum

OCTOBER 29, 2020

The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression. The platform applies machine learning, human genetics, and functional genomics to generate predictive in vitro models that provide insights into disease progression.

Development 45

Development DNA In-Vitro Genome 45

Drug Discovery World

DECEMBER 8, 2023

Andrew Busey , Co-Founder, Form Bio discusses why vertical AI is set to reshape the cell and gene therapy sector. The once-fictional artificial intelligence (AI) depicted in literature and movies has transitioned into a tangible and easily accessible tool in our modern world. Here’s what this means for pharmaceutical leaders and patients.

Gene Therapy 64

Gene Therapy Gene In-Vitro Development 64

Drug Discovery World

DECEMBER 13, 2022

Encouraged by their in vitro findings, the research team is now proposing translational work by setting up large-scale clinical trials involving patients with FCMD. . Japanese researchers propose using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama muscular dystrophy. . Modifying RNA function.

RNA 52

RNA Genetics Gene In-Vitro 52

Drug Discovery World

JUNE 12, 2023

We’ve been attending AACR 2023 every year for a number of years, which has been a progression of us moving from laboratory studies in tissue culture in vitro to see if we had something, to the animal studies and the pharmacology work, and now we’re reporting on very, very mature clinical trial data.

Research 52

Research In-Vitro Doctors Doctor 52

The Pharma Data

DECEMBER 14, 2020

engine along with algorithms tuned to predict BBB permeability played an important role in helping determine which CNS cancers and which genomically-defined subtypes of CNS cancer should be prioritized for development. . We leverage advances in machine learning, genomics, and artificial intelligence by using a proprietary A.I.

Drugs 52

Drugs Genome Genomics DNA 52

Drug Discovery World

DECEMBER 12, 2022

The meeting will focus on the application of genome engineering in identification of novel drug targets through large-scale CRISPR based functional genomics studies, developing advanced cellular and in vivo disease models for target validation, and its applications in therapeutic genome editing. Register here.

Genome 52

Genome Genomics Engineer In-Vivo 52

The Pharma Data

NOVEMBER 14, 2021

The ranking acknowledges Roche’s commitment to sustainability as an integral part of its business strategy Roche performed particularly well in Operational Eco-Efficiency, Environmental and Social Reporting. This is based on an in-depth analysis of economic, social and environmental performance.

In-Vitro 52

In-Vitro Medicine Genome Genomics 52

FDA Law Blog

MAY 25, 2022

It is not uncommon for some in vitro diagnostic tests to suffer from poor positive predictive value, in part due to the rarity of the disease. The VALID Act would give FDA authority to regulate laboratory developed tests and fundamentally change the regulatory paradigm for all in vitro diagnostic tests. (As

Regulation 40

Regulation Genetics In-Vitro Development 40

XTalks

DECEMBER 11, 2023

Medical device companies continue to maintain a crucial role in enhancing patient care and diagnostic precision in 2023. Let’s examine the list of the top ten fastest growing medical device companies in 2023, ranked by their compound annual growth rate (CAGR). In 2021, Axonics achieved an impressive revenue of $180.3

Production 110

Production Sales In-Vitro Development 110

The Pharma Data

JANUARY 11, 2021

Dalcetrapib is a potential anti-viral treatment that binds to the catalytic site of 3CLMpro of SARS-CoV-2 in vitro. Centers for Disease Control and Prevention (CDC) to provide genomic sequencing of SARS-CoV-2 samples. News information is not all-inclusive and updates are published once a week on Tuesdays. . . Diagnostics.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

XTalks

SEPTEMBER 30, 2020

In collaboration with clinicians around the world, Casanova’s team studied the genomes of COVID-19 patients, focusing on a set of 13 genes involved in interferon immunity against influenza. The findings reveal a critical role for IFNs in fighting COVID-19 infection, positioning them to be a potential therapeutic target in the disease.

Antibody 135

Antibody Genetics Research In-Vitro 135

The Pharma Data

NOVEMBER 23, 2021

Roche moment blazoned that new data from its expansive haematology portfolio will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from 11-14 December 2021. The safety profile was similar for Polivy plus R-CHP versus R-CHOP.1 Roche’s Chief Medical Officer and Head of Global Product Development. “

Antibody 52

Antibody In-Vitro Development Genome 52

The Pharma Data

OCTOBER 9, 2021

Roche (SIX RO, ROG; OTCQX RHHBY) now posted that gantenerumab, ananti-amyloid beta antibody developed for subcutaneous administration, has been granted Improvement Rectifier Designation by theU.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice).

Antibody 52

Antibody In-Vitro Trials Development 52

XTalks

NOVEMBER 7, 2022

These tumor-derived entities are used to derive genomic and proteomic data. Liquid biopsy tests in oncology involve isolating entities such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA) and tumor-derived exosomes. The same webinar held a Q&A session with Dr. Bahassi and two other experts from Medpace, Dr. Lyon L.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

The Pharma Data

OCTOBER 14, 2021

This designation is based on data showing that gantenerumab significantly reduced brain amyloid plaque, a pathological hallmark of AD, in the ongoing SCarlet RoAD and Marguerite RoAD open-label extension trials, as well as other studies. Roche’s Chief Medical Officer and Head of Global Product Development.

Antibody 52

Antibody Medicine In-Vitro Trials 52

The Pharma Data

FEBRUARY 25, 2022

“SARS-CoV-2 produces long proteins, called polyproteins, from its RNA genome that must be cleaved into individual proteins by these proteases in an ordered fashion leading to the formation of functional virus enzymes and proteins to start virus replication once it enters a cell,” Murakami explained.

FDA Approval 52

FDA Approval Drugs Protein In-Vitro 52

The Pharma Data

OCTOBER 26, 2021

The AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit is the first jointly-developed product that brings together the expertise and reach of Roche with Foundation Medicine’s pioneering leadership in genomic science. Cancer is a disease of the genome and treatment no longer depends solely on the tissue of origin.

Genome 52

Genome Genomics Research Medicine 52

The Pharma Data

NOVEMBER 12, 2021

EU marketing authorisation follows approvals in Japan, the United Kingdom and Australia Approval based on data demonstrating Ronapreve reduced risk of hospitalisation in certain patients with mild to moderate disease and reduced risk of symptomatic COVID-19 infections in people exposed to the virus.

In-Vitro 40

In-Vitro Medicine Development Marketing 40

The Pharma Data

NOVEMBER 11, 2021

A final decision regarding the blessing of Ronapreve is anticipated from the European Commission in the near future. Roche’s Chief Medical Officer and Head of Global Product Development.”People It has also been conditionally recommended by WHO.

In-Vitro 40

In-Vitro Antibody Medicine Development 40

The Pharma Data

DECEMBER 2, 2020

Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. About Progenity. Progenity, Inc. Progenity, Inc.

In-Vitro 40

In-Vitro Sales Containment Production 40

XTalks

AUGUST 12, 2020

Despite the effectiveness of anti-retroviral therapy (ART) in significantly improving health, quality of life and reducing mortality among HIV-positive individuals, new research shows that persistent infections may be due to the ability of the virus to take refuge in distinct subsets of immune T cells.

RNA 52

RNA Protein DNA In-Vivo 52

The Pharma Data

SEPTEMBER 6, 2020

We remain committed to finding personalised treatment options for people with cancer based on specific genomic or molecular alterations, and we look forward to partnering with Blueprint Medicines to further explore the potential of Gavreto across multiple RET-altered tumour types.”. months, not reached). 2 The most common adverse reactions (?

FDA Approval 52

FDA Approval Medicine In-Vitro Genetics 52

Drug Discovery World

OCTOBER 4, 2022

DDW Editor Reece Armstrong explores some of the trends that will be featured in sessions throughout ELRIG Drug Discovery 2022 and the news behind them. There’s no question that cell and gene therapies have emerged as some of the most promising and innovative medicines on the market. . In 2021, levels of investment hit an all-time high at $22.7

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

The Pharma Data

MARCH 16, 2021

1 lineage gained prominence in late 2020, with each carrying a number of genomic mutations. The cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission. 1.1.7), South Africa (B.1.351), 1.351), and Brazil (P.1). Variants of B.1.1.7, 1.351 and P.1

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52

The Pharma Data

DECEMBER 2, 2020

SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. NASDAQ: PROG) today announced the pricing of its offering of $75.0 The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. million principal amount of notes. per share of common stock.

Sales 40

Sales In-Vitro Containment Development 40

The Pharma Data

SEPTEMBER 16, 2020

New and updated data from across our broad cancer portfolio including phase III results in breast, lung and prostate cancers. New integrated analyses from our tumour agnostic Rozlytrek ® (entrectinib) clinical development programme. Join this event on Roche’s LinkedIn page here. Roche highlights featured at ESMO Virtual Congress 2020.

HR 52

HR Medicine Hormones Trials 52

The Pharma Data

JULY 23, 2021

The antibody combination was granted a Special Approval Pathway under article 14-3 of the Pharmaceuticals and Medical Devices Act. “Ronapreve has been shown to improve survival in high-risk, non-hospitalised COVID-19 patients by reducing the risk of hospitalisation and death.

Antibody 52

Antibody Medicine Production In-Vitro 52

The Pharma Data

AUGUST 27, 2020

FoundationOne Liquid CDx analyses more than 300 cancer-related genes and multiple genomic signatures to help inform treatment decisions for all solid tumour cancers. FoundationOne Liquid CDx adds to Foundation Medicine’s genomic testing portfolio supporting Roche’s mission to deliver truly personalised healthcare.

FDA Approval 52

FDA Approval Genome Genomics Gene 52

Drug Discovery World

JANUARY 12, 2023

The genome is the blueprint for life, consisting of genes made up of thousands of pairs of DNA bases. CRISPR allows researchers to target and edit specific genes in order to better understand the genome, human diseases and the effects of specific mutations. What are organoids? .

Gene Editing 98

Gene Editing Gene Drugs In-Vivo 98

pharmaphorum

MARCH 15, 2022

The TruSight Oncology in vitro diagnostic (IVD) test is being launched first in Europe and according to Illumina’s cancer head Kevin Keegan can match patients with suitable therapies “according to clinical guidelines or clinical trials, based on their tumour profile.”

Gene 52

Gene Genome Genomics Gene Sequencing 52

The Pharma Data

JUNE 26, 2021

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. The EUA is based on results from four randomised, controlled studies that evaluated Actemra/RoActemra for the treatment of COVID-19 in more than 5,500 hospitalised patients. Roche’s Chief Medical Officer and Head of Global Product Development. FDA in this setting, but the U.S.

Clinical Trials 40

Clinical Trials Clinical Trials In-Vitro Antibody 40